Boissel Stephane 4
4 · SANGAMO THERAPEUTICS, INC · Filed Nov 26, 2018
Insider Transaction Report
Form 4
Boissel Stephane
EVP, Corporate Strategy
Transactions
- Award
Stock Option (Right to Buy)
2018-11-23+283,523→ 283,523 totalExercise: $11.08Exp: 2028-11-22→ Common Stock (283,523 underlying)
Footnotes (2)
- [F1]Includes 68,523 option shares granted to the Reporting Person pursuant to the July 20, 2018 Share Purchase Agreement between the Issuer and certain shareholders of TxCell S.A. and 215,000 option shares granted pursuant to the Reporting Person's October 2, 2018 employment agreement with the Issuer.
- [F2]One-quarter (1/4) of the option shares vest and become exercisable after one (1) year measured from the November 23, 2018 grant date, and the remainder of the option shares will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.